Mostrar registro simples

dc.contributor.advisorCaierão, Julianapt_BR
dc.contributor.authorCarvalho, Deise Reispt_BR
dc.date.accessioned2021-05-28T04:25:16Zpt_BR
dc.date.issued2020pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/221602pt_BR
dc.description.abstractPseudomonas aeruginosa is frequently associated with serious infections, affecting mainly hospitalized patients. Often, these microorganisms have a multiresistant profile, including resistance to carbapenems, generating about 35 and 33 thousand deaths yearly in the United States and Europe, respectively. Ceftolozane-tazobactam is the combination of a new beta-lactam with a beta-lactamase inhibitor, developed for the treatment of serious infections caused by P. aeruginosa. The purpose of this descriptive review is to compile information available in current scientific literature regarding the susceptibility and resistance mechanisms to ceftolozane-tazobactam in Brazil and worldwide. The overall susceptibility of P. aeruginosa is > 90%, except in cases of multidrug resistance, being reduced to 72.5-88%. In Brazil, epidemiological data of susceptibility to ceftolozane-tazobactam are still insufficient and stratified. Despite the limited time of clinical use, P. aeruginosa resistant to ceftolozane-tazobactam have been isolated globally. AmpC overexpression and mutations are the main resistance mechanisms reported, directly influencing and increasing MIC values. Resistance reported to this compound is worrying and reinforces the importance of systematic surveillance concerning prevalence of resistance and its mechanisms developed by P. aeruginosa.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoporpt_BR
dc.rightsOpen Accessen
dc.subjectCeftolozane-tazobactamen
dc.subjectFarmáciapt_BR
dc.subjectInfecções por Pseudomonaspt_BR
dc.subjectPseudomonas aeruginosaen
dc.subjectPseudomonas aeruginosapt_BR
dc.subjectSusceptibilityen
dc.subjectMechanisms of resistanceen
dc.titleSusceptibilidade de Pseudomonas aeruginosa à nova combinação de beta-lactâmico com inibidor de beta-lactamase, Ceftolozane-tazobactampt_BR
dc.typeTrabalho de conclusão de graduaçãopt_BR
dc.identifier.nrb001125626pt_BR
dc.degree.grantorUniversidade Federal do Rio Grande do Sulpt_BR
dc.degree.departmentFaculdade de Farmáciapt_BR
dc.degree.localPorto Alegre, BR-RSpt_BR
dc.degree.date2020pt_BR
dc.degree.graduationFarmáciapt_BR
dc.degree.levelgraduaçãopt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples